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Abstract
Patients with advanced HIV disease may exhibit malabsorption of anti-tuberculosis(TB) drugs. We evaluated the effect
of isoniazid (INH) acetylator status on the bioavailability of INH in HIV-infected patients with and without tuberculosis,
based on urinary excretion of the drug. Estimation of INH in urine collected up to 8 hours after oral administration of 300
mg INH were undertaken in 23 TB, 40 HIV and 26 HIV-TB patients. Determination of acetylator status of all these patients
was also carried by differential estimations of INH and acetyl INH in urine collected between 5 and 6 hours after oral
administration of 300 mg INH.
Both slow and rapid acetylators in HIV and HIV-TB groups had significantly lower concentration of INH in urine compared
to TB patients. The percent decrease in urinary excretion of INH was significantly higher in rapid than in slow acetylators,
when compared to the corresponding TB patients. Acetylator status has an impact on the bioavailability of INH. Malbsorption
in patients with advanced HIV disease may lead to decreased bioavailability of INH, particularly in rapid acetylators.
Urinary estimation of INH provides reliable information on the bioavailability of the drug.
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Introduction
Isoniazid (INH) is an essential drug in the treatment of
tuberculosis (TB).  The primary step in its metabolism is
acetylation to acetyl INH.  The metabolising enzyme is a
hepatic N-acetyl transferase, which displays genetic
polymorphism. The rate of acetylation of INH is known to
influence the response to treatment of TB patients with
once-weekly regimens containing INH1,2 but it is of no
prognostic significance when patients are treated with
either daily, thrice-weekly or twice-weekly regimens
containing the drug. It was observed that the failure of
once-weekly regimens was predominantly due to
inadequate exposure (area under the time concentration
curve) and coverage (hours for which a bacteriostatic
concentration of INH 0.2 µg/ml are maintained)3. Weiner
et al4 have reported that once-weekly INH / rifapentine
therapy was less effective than twice-weekly INH /
rifampicin in HIV sero negative TB patients. They
observed an association between INH acetylator status
and treatment outcome in these patients and further
found that low INH concentrations in rapid acetylators
was associated with failure/relapse. It is therefore
essential that adequate INH concentrations are
maintained in blood for good treatment outcome.
In a recent pharmacokinetic study conducted in HIV-
infected patients with advanced disease, we observed
that peak concentration and exposure of INH were
reduced in HIV-infected patients with and without TB
compared to HIV seronegative pulmonary TB patients5.
This study further showed that the differences in these
pharmacokinetic variables were more pronounced in
rapid acetylators than in slow acetylators of INH.  However,
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these differences (except for peak concentration in HIV-
TB rapid group) failed to attain statistical significance.
This could probably be due to the small number of
patients in each sub-group (after classifying them based
on their acetylator status). The study suggested that
acetylator status could influence the bioavailability of INH
in HIV-infected patients, and that rapid acetylators are
likely to be affected more than slow acetylators, in the
event of malabsorption.
Several reports suggest that malabsorption of anti-
mycobacterial drugs occurs in selected HIV-infected
patients, particularly those with advanced disease5-12.
This could lead to decreased blood levels of anti-TB
drugs, thereby causing acquired drug resistance and
treatment failure/relapse. The objective of the present
study was to evaluate the effect of INH acetylator status
on the bioavailability of INH in HIV-infected patients with
and without TB, based on the urinary excretion of the
drug. For this purpose, we carried out estimation of INH
in urine and determination of INH acetylator status in
urine samples collected from patients who participated
in a previous study12.
Methods
Participants
The study was conducted at the Government Hospital of
Thoracic Medicine, Chennai, India. The study
participants comprised of 23 HIV seronegative patients
with pulmonary TB, 40 patients with advanced HIV
disease and diarrhoea (history of recurrent episodes of
watery stools, six to eight times a day for at least 10
consecutive days in a month at the start of study) and 26
patients with HIV infection and TB.  The mean age and
mean body weight of TB, HIV and HIV-TB patients were
41, 34 & 37 years and 40, 43 & 43 kg respectively. All the
participants were males and were admitted to the hospital
at least a day prior to the study. None of the patients was
suffering from significant hepatic or renal dysfunction
(liver transaminases, serum urea and creatinine were
within normal limits). Diagnosis of pulmonary TB was
based on bacteriological investigations (sputum smear
and culture for mycobacteria), which were supported by
clinical and radiological features. HIV infection was
diagnosed on the basis of three positive results (two rapid
tests and ELISA). All TB patients, with and without HIV
infection were receiving standard anti-TB regimens.
None of the HIV-infected patients were receiving
antiretroviral treatment or any stool binders or other
medications known to interfere with the absorption of
INH. The study was conducted after obtaining approval
from the Institutional Ethics Committee and informed
written consent was obtained from all the study
participants.
Conduct of study
Isoniazid was withheld for a period of 72 hours before
start of the study. All the patients were asked to empty
their urinary bladder and this urine sample was
discarded. They received INH (300mg) orally under
supervision after an overnight fast. In addition to this, TB
and HIV-TB received their other regular anti-TB
medications. Uniform breakfast and lunch were provided
to all the patients at 2 and 6 hours after drug
administration. Urine excreted up to 8 hours was
collected in a labeled container. The total volume of
urine was measured, volume noted and aliquots were
stored at -20oC until analysis. The concentration of INH
in all the urine aliquots was estimated by a
spectrophotometric method13. The percent dose of INH
excreted in urine was calculated. All estimations were
undertaken after coding the samples.
Determination of INH acetylator status
The INH acetylator status of all the patients was
determined by differentially estimating the concentration
of INH and its primary metabolite, acetyl INH in urine
excreted between 5 and 6 hours after oral administration
of 300 mg INH, and by calculating the molar ratio of
acetyl INH to INH. A ratio of 2.0 or more denoted the
acetylator status to be rapid14.
Statistical analysis
Analysis of data was performed using SPSS (version 10.5)
package. The significance of differences in mean
percent dose between two study groups was evaluated
using unpaired t-test and between more than two groups
using Bonferoni multiple comparison test (one-way
Anova). The significance was taken at 5% level.
Results and Discussion
The number of slow and rapid acetylators of INH among
TB, HIV and HIV-TB patients were 16 & 7, 22 & 18 and 11
& 15 respectively. The percent dose of INH excreted in
urine up to 8 hours was compared between HIV (with
and without TB) and TB patients among slow and rapid
acetylators independently. Likewise, the percent
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decrease in INH excretion in HIV and HIV-TB patients
was calculated separately for slow and rapid acetylators
against the corresponding TB patients in both these
groups. There was a significant decrease in percent
dose of INH excreted in urine in HIV and HIV-TB patients
when compared to TB patients in both slow and rapid
acetylators of INH (p<0.01) (Table 1). While the percent
decrease in urinary excretion of INH in slow acetylators
in HIV and HIV-TB patients against TB patients was 28%
and 27% respectively, the corresponding values among
rapid acetylators was 47% and 55% respectively.  The
difference in urinary INH values between HIV and HIV-
TB patients was not statistically significant.
The metabolizing enzyme of INH is a hepatic N-acetyl
transferase, which displays genetic polymorphism. The
difference in the two phenotypes of this enzyme, namely,
slow and rapid acetylators of INH is due to difference in
quantity rather than quality of the enzyme, the rapid
acetylators having 4-5 times the quantity of the enzyme
as the slow acetylators. It is therefore expected that rapid
acetylators will have enhanced metabolism of INH than
slow acetylators, and that blood levels and urinary
excretion of INH will be lower in rapid than in slow
acetylators. A significant effect of acetylator status on
blood levels of INH has been reported4, 5, 11, 15. This aspect
was further confirmed in this study, where a significant
decrease in urinary excretion of INH in rapid compared
to slow acetylators in all three groups of patients was
observed. This study further demonstrated that the
percent decrease in INH excretion in HIV and HIV-TB
patients was higher in rapid than in slow acetylators.
In the Revised National TB Control Programme, where
INH is administered thrice-weekly, INH acetylator status
may not play a role in treatment outcome as
demonstrated in certain studies1, 2. Despite a 50%
reduction in the percent dose of INH excreted in urine in
rapid than in slow acetylators among TB patients, as
seen in this study, the treatment outcome is expected to
be similar irrespective of their INH acetylator status.
However, the presence of malabsorption in rapid
acetylators with advanced HIV disease (with and without
TB) may lead to decreased bioavailability of INH. This
could have implications for treatment of TB in a subset
of HIV-infected patients who may require higher dose of
INH or daily treatment. On the other hand slow acetylators
are less likely to be affected, since their urinary INH levels
were higher than TB patients who were rapid acetylators.
This has been confirmed by our earlier study, where we
observed differences in peak concentration and
exposure between TB and HIV patients to be significant
only among rapid acetylators of INH5.
To the best of our knowledge, there are no reports
available on the effect of INH acetylator status on the
bioavailability of INH in HIV-infected patients.  Our
findings suggest that patients with HIV, TB, diarrhoea
who are rapid acetylators might have reduced
bioavailability of INH. Urinary INH estimations offer a
simple and reliable non invasive procedure to obtain
information on the bioavailability of INH. A large
prospective trial is required to correlate INH acetylator
status with treatment outcome and emergence of
mycobacterial drug resistance in patients with advanced
HIV disease.
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Percent dose of INH (Mean + SD)
INH acetylator status TB(S-16; R-7) HIV(S-22; R-18) HIV-TB(S-11; R-15)
Slow 31.71+7.98 22.80*+7.19 (28%) 23.28*+4.24 (27%)
Rapid 15.83+2.13 8.38*+3.62 (47%) 7.12*+3.02 (55%)
*p< 0.01 (vs TB patients)
Percent decrease vs TB patients are given in parentheses
S = Slow acetylator of INH, R = Rapid acetylator of INH
Table 1 Urinary excretion of INH in the different study groups
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